<i>NPY</i> Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

<i>NPY</i> Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

There is a need for biomarkers to improve the clinical benefit from systemic treatment of colorectal cancer. We designed a prospective, clinical study where patients receiving regorafenib as last-line treatment had sequential blood samples drawn. Effect and toxicity was monitored. The primary clinic...

Full description

Bibliographic Details
Main Authors: Lars Henrik Jensen, René Olesen, Lone Noergaard Petersen, Anders Kindberg Boysen, Rikke Fredslund Andersen, Jan Lindebjerg, Lise Nottelmann, Caroline Emilie Brenner Thomsen, Birgitte Mayland Havelund, Anders Jakobsen, Torben Frøstrup Hansen
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
ctdna
<i>npy</i> methylation
biomarker
colorectal cancer
regorafenib
Online Access:https://www.mdpi.com/2072-6694/11/11/1649

Internet

https://www.mdpi.com/2072-6694/11/11/1649

Similar Items